Severe Capecitabine Toxicity Associated With a Rare Variant Identified Through Whole-Genome Sequencing.
作者信息
Ly Reynold C, Schmidt Remington E, Kiel Patrick J, Pratt Victoria M, Schneider Bryan P, Radovich Milan, Offer Steven M, Diasio Robert B, Skaar Todd C
机构信息
Department of Medicine, Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, IN.
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN.
出版信息
JCO Precis Oncol. 2020 Jun 12;4. doi: 10.1200/PO.20.00067. eCollection 2020.
Abstract
摘要
相似文献
1
Severe Capecitabine Toxicity Associated With a Rare Variant Identified Through Whole-Genome Sequencing.
JCO Precis Oncol. 2020 Jun 12;4. doi: 10.1200/PO.20.00067. eCollection 2020.
2
Tolerance-based capecitabine dose escalation after DPYD genotype-guided dosing in heterozygote DPYD variant carriers: a single-center observational study.
Anticancer Drugs. 2019 Apr;30(4):410-415. doi: 10.1097/CAD.0000000000000748.
3
Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers.
Eur J Cancer. 2018 Nov;104:210-218. doi: 10.1016/j.ejca.2018.07.138. Epub 2018 Oct 23.
4
New advances in DPYD genotype and risk of severe toxicity under capecitabine.
PLoS One. 2017 May 8;12(5):e0175998. doi: 10.1371/journal.pone.0175998. eCollection 2017.
5
Severe toxicity to capecitabine due to a new variant at a donor splicing site in the dihydropyrimidine dehydrogenase gene.
Cancer Manag Res. 2018 Oct 11;10:4517-4522. doi: 10.2147/CMAR.S174470. eCollection 2018.
6
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
Lancet Oncol. 2018 Nov;19(11):1459-1467. doi: 10.1016/S1470-2045(18)30686-7. Epub 2018 Oct 19.
7
A Novel Variant Associated With Severe Toxicity of Fluoropyrimidines: Role of Pre-emptive Genotype Screening.
Front Oncol. 2018 Jul 24;8:279. doi: 10.3389/fonc.2018.00279. eCollection 2018.
8
Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysis.
Int J Cancer. 2019 May 1;144(9):2347-2354. doi: 10.1002/ijc.32022. Epub 2019 Jan 4.
9
Evaluation of clinical implementation of prospective DPYD genotyping in 5-fluorouracil- or capecitabine-treated patients.
Pharmacogenomics. 2016 May;17(7):721-9. doi: 10.2217/pgs-2016-0013. Epub 2016 May 16.
10
Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine-associated toxicity.
Int J Cancer. 2016 Jun 1;138(11):2752-61. doi: 10.1002/ijc.30014. Epub 2016 Feb 19.
引用本文的文献
1
Pharmacogenetics of DPYD and treatment-related mortality on fluoropyrimidine chemotherapy for cancer patients: a meta-analysis and trial sequential analysis.
BMC Cancer. 2024 Sep 30;24(1):1210. doi: 10.1186/s12885-024-12981-5.
2
Development of a Multifaceted Program for Pharmacogenetics Adoption at an Academic Medical Center: Practical Considerations and Lessons Learned.
Clin Pharmacol Ther. 2024 Oct;116(4):914-931. doi: 10.1002/cpt.3402. Epub 2024 Aug 21.
3
Clinical Implementation of Rare and Novel Variants for Personalizing Fluoropyrimidine Treatment: Challenges and Opportunities.
Int J Biol Sci. 2024 Jul 2;20(10):3742-3759. doi: 10.7150/ijbs.97686. eCollection 2024.
4
Approach for Phased Sequence-Based Genotyping of the Critical Pharmacogene Dihydropyrimidine Dehydrogenase ().
Int J Mol Sci. 2024 Jul 11;25(14):7599. doi: 10.3390/ijms25147599.
5
DPYD genetic polymorphisms in non-European patients with severe fluoropyrimidine-related toxicity: a systematic review.
Br J Cancer. 2024 Aug;131(3):498-514. doi: 10.1038/s41416-024-02754-z. Epub 2024 Jun 17.
6
Rare genetic variant burden in DPYD predicts severe fluoropyrimidine-related toxicity risk.
Biomed Pharmacother. 2022 Oct;154:113644. doi: 10.1016/j.biopha.2022.113644. Epub 2022 Sep 2.
7
Testing for Dihydropyrimidine Dehydrogenase Deficiency to Individualize 5-Fluorouracil Therapy.
Cancers (Basel). 2022 Jun 30;14(13):3207. doi: 10.3390/cancers14133207.
8
A narrative review of genetic factors affecting fluoropyrimidine toxicity.
Precis Cancer Med. 2021 Dec;4. doi: 10.21037/pcm-21-17. Epub 2021 Dec 30.
本文引用的文献
1
Dose modification for safe treatment of a compound complex heterozygous variant carrier with 5-fluorouracil.
JCO Precis Oncol. 2018;2. doi: 10.1200/po.18.00179. Epub 2018 Oct 3.
2
Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis.
Pharmacol Res. 2020 Feb;152:104594. doi: 10.1016/j.phrs.2019.104594. Epub 2019 Dec 12.
3
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines.
Eur J Hum Genet. 2020 Apr;28(4):508-517. doi: 10.1038/s41431-019-0540-0. Epub 2019 Nov 19.
4
Identifying a Novel DPYD Polymorphism Associated with Severe Toxicity to 5-FU Chemotherapy in a Saudi Patient.
Case Rep Genet. 2019 Aug 21;2019:5150725. doi: 10.1155/2019/5150725. eCollection 2019.
5
Rare Dihydropyrimidine Dehydrogenase Variants and Toxicity by Floropyrimidines: A Case Report.
Front Oncol. 2019 Mar 11;9:139. doi: 10.3389/fonc.2019.00139. eCollection 2019.
6
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
Lancet Oncol. 2018 Nov;19(11):1459-1467. doi: 10.1016/S1470-2045(18)30686-7. Epub 2018 Oct 19.
7
A Novel Variant Associated With Severe Toxicity of Fluoropyrimidines: Role of Pre-emptive Genotype Screening.
Front Oncol. 2018 Jul 24;8:279. doi: 10.3389/fonc.2018.00279. eCollection 2018.
8
Gene-Specific Variant Classifier (DPYD-Varifier) to Identify Deleterious Alleles of Dihydropyrimidine Dehydrogenase.
Clin Pharmacol Ther. 2018 Oct;104(4):709-718. doi: 10.1002/cpt.1020. Epub 2018 Feb 2.
9
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update.
Clin Pharmacol Ther. 2018 Feb;103(2):210-216. doi: 10.1002/cpt.911. Epub 2017 Nov 20.
10
Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing.
Biochim Biophys Acta Mol Basis Dis. 2017 Mar;1863(3):721-730. doi: 10.1016/j.bbadis.2016.12.010. Epub 2016 Dec 24.
Zotero 插件